Integrative analysis of the colorectal cancer proteome

potential clinical impact

Abdo Alnabulsi, Graeme I. Murray*

*Corresponding author for this work

Research output: Contribution to journalReview article

11 Citations (Scopus)
6 Downloads (Pure)

Abstract

Introduction: Colorectal cancer (CRC) is one of the commonest types of cancer that affects a significant proportion of the population and is a major contributor to cancer related mortality. The relatively poor survival rate of CRC could be improved through the identification of clinically useful biomarkers.
Area covered: This review highlights the need for biomarkers and discusses recent proteomics discoveries in the aspects of CRC clinical practice including diagnosis, prognosis, therapy, screening, and molecular pathological epidemiology (MPE). Studies have been evaluated in relation to biomarker target, methodology, sample selection, limitations, and potential impact. Finally, the progress in proteomic approaches is briefly discussed, and the main difficulties facing the translation of proteomics biomarkers into the clinical practice are highlighted.

Expert opinion: The establishment of specific guidelines, best practice recommendations and the improvement in proteomic strategies will significantly improve the prospects for developing clinically useful biomarkers.
Original languageEnglish
Pages (from-to)917-927
Number of pages11
JournalExpert Review of Proteomics
Volume13
Issue number10
Early online date19 Sep 2016
DOIs
Publication statusPublished - Oct 2016

Keywords

  • Biomarkers
  • colorectal cancer
  • diagnosis
  • prognosis
  • proteomics
  • predictive screening
  • MOLECULAR PATHOLOGICAL EPIDEMIOLOGY
  • URINARY PGE-M
  • COLON-CANCER
  • BIOMARKER DISCOVERY
  • PRECISION MEDICINE
  • PLASMA BIOMARKERS
  • MASS-SPECTROMETRY
  • TUMOR-MARKERS
  • BIG DATA
  • RISK

Cite this

Integrative analysis of the colorectal cancer proteome : potential clinical impact. / Alnabulsi, Abdo; Murray, Graeme I.

In: Expert Review of Proteomics, Vol. 13, No. 10, 10.2016, p. 917-927.

Research output: Contribution to journalReview article

@article{18f25f17ade54f4f84c21fa48003040e,
title = "Integrative analysis of the colorectal cancer proteome: potential clinical impact",
abstract = "Introduction: Colorectal cancer (CRC) is one of the commonest types of cancer that affects a significant proportion of the population and is a major contributor to cancer related mortality. The relatively poor survival rate of CRC could be improved through the identification of clinically useful biomarkers.Area covered: This review highlights the need for biomarkers and discusses recent proteomics discoveries in the aspects of CRC clinical practice including diagnosis, prognosis, therapy, screening, and molecular pathological epidemiology (MPE). Studies have been evaluated in relation to biomarker target, methodology, sample selection, limitations, and potential impact. Finally, the progress in proteomic approaches is briefly discussed, and the main difficulties facing the translation of proteomics biomarkers into the clinical practice are highlighted.Expert opinion: The establishment of specific guidelines, best practice recommendations and the improvement in proteomic strategies will significantly improve the prospects for developing clinically useful biomarkers.",
keywords = "Biomarkers, colorectal cancer, diagnosis, prognosis, proteomics, predictive screening, MOLECULAR PATHOLOGICAL EPIDEMIOLOGY, URINARY PGE-M, COLON-CANCER, BIOMARKER DISCOVERY, PRECISION MEDICINE, PLASMA BIOMARKERS, MASS-SPECTROMETRY, TUMOR-MARKERS, BIG DATA, RISK",
author = "Abdo Alnabulsi and Murray, {Graeme I.}",
year = "2016",
month = "10",
doi = "10.1080/14789450.2016.1233062",
language = "English",
volume = "13",
pages = "917--927",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "TAYLOR & FRANCIS LTD",
number = "10",

}

TY - JOUR

T1 - Integrative analysis of the colorectal cancer proteome

T2 - potential clinical impact

AU - Alnabulsi, Abdo

AU - Murray, Graeme I.

PY - 2016/10

Y1 - 2016/10

N2 - Introduction: Colorectal cancer (CRC) is one of the commonest types of cancer that affects a significant proportion of the population and is a major contributor to cancer related mortality. The relatively poor survival rate of CRC could be improved through the identification of clinically useful biomarkers.Area covered: This review highlights the need for biomarkers and discusses recent proteomics discoveries in the aspects of CRC clinical practice including diagnosis, prognosis, therapy, screening, and molecular pathological epidemiology (MPE). Studies have been evaluated in relation to biomarker target, methodology, sample selection, limitations, and potential impact. Finally, the progress in proteomic approaches is briefly discussed, and the main difficulties facing the translation of proteomics biomarkers into the clinical practice are highlighted.Expert opinion: The establishment of specific guidelines, best practice recommendations and the improvement in proteomic strategies will significantly improve the prospects for developing clinically useful biomarkers.

AB - Introduction: Colorectal cancer (CRC) is one of the commonest types of cancer that affects a significant proportion of the population and is a major contributor to cancer related mortality. The relatively poor survival rate of CRC could be improved through the identification of clinically useful biomarkers.Area covered: This review highlights the need for biomarkers and discusses recent proteomics discoveries in the aspects of CRC clinical practice including diagnosis, prognosis, therapy, screening, and molecular pathological epidemiology (MPE). Studies have been evaluated in relation to biomarker target, methodology, sample selection, limitations, and potential impact. Finally, the progress in proteomic approaches is briefly discussed, and the main difficulties facing the translation of proteomics biomarkers into the clinical practice are highlighted.Expert opinion: The establishment of specific guidelines, best practice recommendations and the improvement in proteomic strategies will significantly improve the prospects for developing clinically useful biomarkers.

KW - Biomarkers

KW - colorectal cancer

KW - diagnosis

KW - prognosis

KW - proteomics

KW - predictive screening

KW - MOLECULAR PATHOLOGICAL EPIDEMIOLOGY

KW - URINARY PGE-M

KW - COLON-CANCER

KW - BIOMARKER DISCOVERY

KW - PRECISION MEDICINE

KW - PLASMA BIOMARKERS

KW - MASS-SPECTROMETRY

KW - TUMOR-MARKERS

KW - BIG DATA

KW - RISK

U2 - 10.1080/14789450.2016.1233062

DO - 10.1080/14789450.2016.1233062

M3 - Review article

VL - 13

SP - 917

EP - 927

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 10

ER -